Steatohepatitis/Metabolic Liver Disease News

Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.

Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally. The prevalence has risen in parallel with epidemics of obesity and type 2 diabetes.

Millions of dollars have been spent trying to find medications that could treat this complex disorder. The focus has been on drugs for more severe disease, as it leads to complications, and early stages have been somewhat ignored.

Although use of glucagon-like peptide-1 agonists for diabetes and weight loss has soared with indications now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis, the jury is still out on its benefit.

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.

Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis, with no dose reduction needed based on pharmacokinetics, according to data.

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data.

BOSTON — Midlife women reporting bothersome hot flashes are more likely to receive a diagnosis of metabolic dysfunction-associated steatotic liver disease regardless of hormone therapy use, according to a speaker.

Patients with metabolic dysfunction-associated steatohepatitis who weigh more than 100 kg or a BMI more than 35 kg/m² had “slightly better” response with a 100 mg dose of Rezdiffra, according to data presented at EASL Congress.

At 15 years of follow-up, metabolic surgery “was not only safe” but also significantly reduced major adverse liver outcomes and decompensation in patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.